Compare OTH & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTH | ADVM |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7M | 94.6M |
| IPO Year | 2025 | 2014 |
| Metric | OTH | ADVM |
|---|---|---|
| Price | $3.20 | $4.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | 154.8K | ★ 495.1K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $105,737,814.00 | N/A |
| Revenue This Year | N/A | $1,192.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.58 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $3.01 | $1.78 |
| 52 Week High | $3.90 | $6.12 |
| Indicator | OTH | ADVM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.88 |
| Support Level | N/A | $4.15 |
| Resistance Level | N/A | $4.23 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 96.02 |
Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Boat Sales and Azure Funding. Boat Sales includes Specializing in the buying, selling, and wholesaling of yachts and boats, having a boat dealership created to run Yellow Fin sales in Miami; and Azure Funding includes a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.